Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes

Table 2 Events, person-years at risk and HR for NAION according to exposure of once-weekly semaglutide

	Events of NAION	Person-years at risk (years)	Incidence rate (per 1000 person-years)	HR (95% CI)
Semaglutide				Crude model	Mutivariable model*
Yes	67	294,395	0·228	2·57 (1·92 − 3·45)†	2·19 (1·54 − 3·12)†
No	151	1,620,725	0·093	Reference	Reference

CI = confidence interval. HR = hazard ratio. NAION = nonarteritic anterior ischemic optic neuropathy *Multivariable model adjusted for sex, age, marital status, duration of diabetes, hemoglobin A1c, estimated glomerular filtration rate, cardiovascular disease, use of insulin, use of cholesterol lowering medicine, and use of blood pressure lowering medicine. †Statistically significant

ISSN: 2056-9920